Bispecific antibody
US12325746B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2020 |
| Grant date | Jun 10, 2025 |
| Priority date | — |
| Expiry date | Oct 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.